Table IIIa.
Definition and values of the indicators evaluating diagnostic procedures, overall and across tumour types.
| Indicator code | Description Proportion of patients: | No. eligible overall | Value (%) | ||||
|---|---|---|---|---|---|---|---|
| Oral cavity N = 469 |
Salivary glands N = 79 |
Pharynx N = 314 |
Larynx N = 567 |
Overall | |||
| D1 | Having performed a cyto-histological assessment* of the primary tumour in the 180 days before the first treatment | 1299 | 77.7 | 77.1 | 90.6 | 82.7 | 82.6 |
| D2 | With distant metastasis risk tumour type† undergoing systemic staging with PET-CT or whole body computed tomography | 249 | 41.0 | 41.0 | |||
*ICD-9 codes. Biopsies: cranial nerves, 04.11, 04.12, 05.11; oral cavity, 24.11, 25.01, 25.02, 27.21-27.24; salivary glands, 26.11, 26.12; pharynx, 28.11, 29.12; larynx, 31.43, 31.45; facial bones, 76.11; soft tissues, 83.21; lymph-nodes, 40.11. Microscopic examination of specimen from: ear, nose, throat, and larynx, 90.3; lymph-nodes, 90.7. Pharyngoscopy: 29.11; Laryngoscopy: 31.42.
† rhino and hypo-pharynx.